DAVIS JOHN C. JR 4
4 · Magenta Therapeutics, Inc. · Filed Jan 3, 2020
Insider Transaction Report
Form 4
DAVIS JOHN C. JR
Chief Medical Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2020-01-02−11,294→ 224,831 totalExercise: $9.49Exp: 2028-04-25→ Common Stock (11,294 underlying) - Sale
Common Stock
2020-01-02$15.04/sh−11,294$169,817→ 8,304 total - Exercise/Conversion
Common Stock
2020-01-02$9.49/sh+11,294$107,180→ 19,598 total
Footnotes (3)
- [F1]This trade is pursuant to an active 10b5-1 plan.
- [F2]This transaction was executed in multiple trades at prices ranging from $15.00 to $15.09. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
- [F3]25% vested on February 16, 2019 with the remaining 75% vesting in 12 equal quarterly installments thereafter.